Funding rounds, M&A, IPOs, and market analysis—where capital is flowing and why the tape moves.
BlossomHill Therapeutics and Latigo Biotherapeutics both reached the Nasdaq Global Select Market with proceeds above their original IPO targets. The pair add to a 2026 biotech class that BioSpace said is already the largest since 2021 once their offerings are counted.
BlossomHill Therapeutics and Latigo Biotherapeutics both reached the Nasdaq Global Select Market with proceeds above their original IPO targets. The pair add to a 2026 biotech class that BioSpace said is already the largest since 2021 once their offerings are counted.
READ MORE
Braveheart Bio is set to debut on Nasdaq with an upsized IPO expected to raise $382.5 million. The offering adds to a broader rebound in biotech listings after a market that was largely shut for most of 2025.
July’s funding landscape underscores strong investor confidence in health tech, with several companies announcing major investment rounds that signal continued transformation across healthcare delivery and digital innovation.
MedCity News’ Bullseye event delivered a day of ambitious, unorthodox commentary on the state of healthcare investment and pharmaceutical innovation, featuring perspectives rarely heard at other industry conferences.
In a testament to the durability of reverse mergers as a pathway to public markets, private immunology-focused biotechs Caldera Therapeutics and Vidya Therapeutics have together raised $478 million through separate go-public deals. These transactions underscore shifting capital strategies amid a challenging biotech investment climate.
Candid Health has landed $120 million in Series D funding to advance its AI-powered revenue cycle management (RCM) platform, drawing investments from key venture capital and growth equity players. This milestone reflects escalating demand for automation and intelligence in healthcare's complex administrative back end.
Health tech investors are increasingly looking for founders who understand the limits of their expertise and build teams to fill in crucial competence gaps, as revealed in recent discussions at MedCity News’ Bullseye event.
BioSpace has introduced an IPO dashboard to keep the industry updated on the performance of biotechnology companies that went public in 2026. This tracking tool reflects broader trends in investor sentiment and sector momentum during a dynamic period for the industry.
As economic headwinds reshape biotech capital markets, hybrid financing models are gaining momentum in the life sciences sector, offering new avenues for growth amid uncertainty.
Juno Bio has raised $3.8 million in new funding to support research and innovative solutions for vaginal health, backed by Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator.
Digital health sector investment reached $7.4 billion in H1 2026, but with AI solutions becoming commonplace, the competitive edge is shifting from technology to deep domain expertise.
